297 related articles for article (PubMed ID: 23222419)
1. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.
Helal I; McFann K; Reed B; Yan XD; Schrier RW; Fick-Brosnahan GM
Nephrol Dial Transplant; 2013 Feb; 28(2):380-5. PubMed ID: 23222419
[TBL] [Abstract][Full Text] [Related]
2. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
Kim K; Trott JF; Gao G; Chapman A; Weiss RH
BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
[TBL] [Abstract][Full Text] [Related]
3. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G;
PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
[TBL] [Abstract][Full Text] [Related]
4. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
[TBL] [Abstract][Full Text] [Related]
5. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.
Brosnahan GM; You Z; Wang W; Gitomer BY; Chonchol M
Curr Hypertens Rev; 2021; 17(3):228-237. PubMed ID: 32807060
[TBL] [Abstract][Full Text] [Related]
6. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
[TBL] [Abstract][Full Text] [Related]
8. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.
Iseki K; Ikemiya Y; Inoue T; Iseki C; Kinjo K; Takishita S
Am J Kidney Dis; 2004 Oct; 44(4):642-50. PubMed ID: 15384015
[TBL] [Abstract][Full Text] [Related]
9. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
Rodenbach KE; Schneider MF; Furth SL; Moxey-Mims MM; Mitsnefes MM; Weaver DJ; Warady BA; Schwartz GJ
Am J Kidney Dis; 2015 Dec; 66(6):984-92. PubMed ID: 26209544
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
Nowak KL; Cadnapaphornchai MA; Chonchol MB; Schrier RW; Gitomer B
Am J Nephrol; 2016; 44(3):171-8. PubMed ID: 27548646
[TBL] [Abstract][Full Text] [Related]
11. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
[TBL] [Abstract][Full Text] [Related]
12. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
[TBL] [Abstract][Full Text] [Related]
13. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
[TBL] [Abstract][Full Text] [Related]
14. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Coban M; Inci A
Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
[TBL] [Abstract][Full Text] [Related]
15. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients.
Chen H; Watnick T; Hong SN; Daly B; Li Y; Seliger SL
BMC Nephrol; 2019 Oct; 20(1):386. PubMed ID: 31653199
[TBL] [Abstract][Full Text] [Related]
17. Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease.
Lai S; Mittherhofer AP; Cianci R; Riviello L; Vocaturi M; Mastroluca D; Ciccariello M; Von Heland M; Ricciuti GP; Salciccia S; Mazzaferro S
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2734-2743. PubMed ID: 31002123
[TBL] [Abstract][Full Text] [Related]
18. Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients.
Sans L; Pascual J; Radosevic A; Quintian C; Ble M; Molina L; Mojal S; Ballarin JA; Torra R; Fernández-Llama P
Medicine (Baltimore); 2016 Dec; 95(49):e5595. PubMed ID: 27930582
[TBL] [Abstract][Full Text] [Related]
19. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
[TBL] [Abstract][Full Text] [Related]
20. Kidney volume and function in autosomal dominant polycystic kidney disease.
Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T
Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
